Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 2,195 shares of the business’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $18.03, for a total value of $39,575.85. Following the completion of the sale, the director directly owned 337,059 shares of the company’s stock, valued at $6,077,173.77. The trade was a 0.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Maplight Therapeutics Price Performance

Maplight Therapeutics stock traded down $0.28 during mid-day trading on Tuesday, reaching $18.02. The stock had a trading volume of 97,940 shares, compared to its average volume of 185,529. Maplight Therapeutics, Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $21.55. The company has a 50-day simple moving average of $17.83. The stock has a market cap of $817.57 million and a price-to-earnings ratio of -0.48.

Maplight Therapeutics (NASDAQ:MPLT) last released its quarterly earnings data on Thursday, December 4th. The company reported ($37.18) earnings per share for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Ratings Changes

A number of brokerages have recently weighed in on MPLT. Stifel Nicolaus initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued a “buy” rating and a $28.00 target price on the stock. Zacks Research raised Maplight Therapeutics to a “hold” rating in a research report on Monday, November 24th. Leerink Partners started coverage on Maplight Therapeutics in a research report on Friday, November 21st. They set an “outperform” rating and a $30.00 target price for the company. Jefferies Financial Group assumed coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $32.00 price target on the stock. Finally, Weiss Ratings assumed coverage on shares of Maplight Therapeutics in a report on Thursday, January 22nd. They set a “sell (e)” rating for the company. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.00.

Institutional Trading of Maplight Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Fcpm Iii Services B.V. bought a new stake in Maplight Therapeutics during the fourth quarter valued at $56,672,000. T. Rowe Price Investment Management Inc. bought a new position in shares of Maplight Therapeutics during the 4th quarter valued at about $49,154,000. Goldman Sachs Group Inc. purchased a new position in shares of Maplight Therapeutics during the 4th quarter valued at about $34,026,000. Nan Fung Group Holdings Ltd purchased a new position in shares of Maplight Therapeutics during the 4th quarter valued at about $17,060,000. Finally, 5AM Venture Management LLC bought a new stake in Maplight Therapeutics in the 4th quarter worth approximately $16,687,000.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.